Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-24

Study Completion Date

2017-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to assess the safety, tolerability, and biomarkers of protection in healthy malaria-naïve adults, who will receive bites from Anopheles stephensi mosquitoes either infected with Plasmodium falciparum Sporozoites (PfRAS) (true-immunization) or noninfected (mock-immunization).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Malaria Challenge in Healthy Volunteers

NCT01500980

Malaria

COMPLETED PHASE1

Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

NCT03168854

Plasmodium Falciparum Infection

COMPLETED PHASE1

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

NCT01397227

Malaria

COMPLETED PHASE1/PHASE2

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

NCT03341754

Malaria

COMPLETED PHASE1

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

NCT02015091

Malaria

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1 open-labeled study. In addition to safety and tolerability of Plasmodium falciparum Sporozoites (PfRAS), this study is a comprehensive, systems biology-based effort to identify and validate biomarkers of protection with PfRAS immunization, comparing sterility protected to nonprotected study subjects. The goal of the trial design is to achieve approximately 50% sterile protection in order to facilitate the identification of biomarkers and correlates of protection.

Following true-immunization or mock-immunization, study subjects and nonimmunized infectivity controls will receive a challenge via the bites of 5 An stephensi mosquitoes carrying infectious P falciparum sporozoites within a controlled clinical environment (controlled human malaria infection, CHMI) to determine the level of sterile protection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: PfRAS-infected

5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.

Challenge occurs 3 weeks after final immunization.

Group Type EXPERIMENTAL

PfRAS

Intervention Type BIOLOGICAL

Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes

Challenge

Intervention Type OTHER

5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Cohort 1: Noninfected

Placebo immunization. 5 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 noninfected bites.

Challenge occurs 3 weeks after final immunization.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Administered by the bite of noninfected Anopheles stephensi mosquitoes

Challenge

Intervention Type OTHER

5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Cohort 1: Nonimmunized

No protective intervention given.

Challenge occurs directly after screening.

Group Type OTHER

Challenge

Intervention Type OTHER

5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Cohort 2: PfRAS-infected

3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.

Challenge occurs 3 weeks after final immunization.

Group Type EXPERIMENTAL

PfRAS

Intervention Type BIOLOGICAL

Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes

Challenge

Intervention Type OTHER

5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Cohort 2: Noninfected

Placebo. 3 to 7 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.

Challenge occurs 3 weeks after final immunization.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Administered by the bite of noninfected Anopheles stephensi mosquitoes

Challenge

Intervention Type OTHER

5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Cohort 2: Nonimmunized

No protective intervention given.

Challenge occurs directly after screening.

Group Type OTHER

Challenge

Intervention Type OTHER

5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Hyperimmunity PfRAS-infected

Cohort 1 sub-cohort

3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. This arm will receive the first 3 immunizations of Cohort 2.

Challenge occurs at the same time as Cohort 2 (3-20 weeks after the final immunization)

Group Type EXPERIMENTAL

PfRAS

Intervention Type BIOLOGICAL

Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes

Challenge

Intervention Type OTHER

5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PfRAS

Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes

Intervention Type BIOLOGICAL

Placebo

Administered by the bite of noninfected Anopheles stephensi mosquitoes

Intervention Type BIOLOGICAL

Challenge

5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

True-immunization PfRAS infected Anopheles stephensi mosquitoes Mock-immunization Noninfected Anopheles stephensi mosquites

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults (male or non-pregnant, non-breastfeeding female) 18-50 years of age (inclusive).
* Available and willing to participate for duration of study.
* Able and willing to provide written informed consent.
* Able to complete an Assessment of Understanding with a score of at least 70% correct.
* In good general health with no clinically significant health problems as established by medical history, physical exam and laboratory screening.
* Females of childbearing potential must have a negative pregnancy test at screening and agree to not become pregnant or breastfeed for the duration of the study. She must be willing to use a reliable form of contraception during the study. Reliable forms of birth control include use of condoms, diaphragm or cervical cap, birth control pills, IUD or sperm killing products.
* Agree to refrain from blood donation (except as required in this study) for 3 years following P falciparum challenge.
* Agree not to travel to a malaria-endemic region during the study.
* Good peripheral venous access.

Exclusion Criteria

* Positive HIV, HBsAg, or HCV serology.
* Positive sickle cell screening test, including evidence of sickle trait.
* Reactivity by CSP or AMA1 ELISpot assay or ELISA as determined by IMRAS Study Specific Procedure #204.
* Anemia (below normal reference laboratory value of hemoglobin) on screening.
* Weight less than 110 pounds (this does not apply to infectivity controls as it is a weight cut-off for subjects undergoing leukapheresis procedure)
* Any history of malaria infection or travel to a malaria endemic region within 6 months prior to first immunization.
* History of long-term residence (\> 5 years) in area known to have significant transmission of Pf \[cumulative lifetime exposure\].
* Use of systemic immunosuppressant pharmacotherapy for greater than 10 days within 60 days of scheduled first immunization (inhaled and topical steroids are allowed; short duration or tapered corticosteroid regimens of 10 days or less that have been discontinued prior to first immunization are allowed).
* Current significant medical condition (cardiovascular, hepatic, renal, pulmonary, or hematological) or evidence of any other serious underlying medical condition identified by medical history, physical examination, or laboratory examination (includes bleeding disorders).
* Plan for surgery between enrollment and day 28 post-challenge (minor procedures, elective corrective vision surgery, and dental procedures are allowed).
* Receipt of immunoglobulin and/or any blood products within 90 days of scheduled leukapheresis or immunization. Version 13.0 (08May2015) 70 US Government Proprietary Deleted: 8 Deleted: 08JULY2014
* Has evidence of increased cardiovascular disease risk (defined as \> 5%-10%, 5-year risk) as determined by the method of Gaziano (2008). Risk factors include sex, age (years), systolic blood pressure (mm Hg), smoking status, body mass index (BMI, kg/m2), reported diabetes status, and blood pressure.
* An abnormal electrocardiogram (ECG), defined as one showing pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial contractions; right or left bundle branch block; or advanced (secondary or tertiary) A-V heart block.
* History of a splenectomy.
* History of any other illness or condition that, in the investigator's judgment, may substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives. This may include psychiatric disorders (such as personality disorders, anxiety disorders, or schizophrenia) or behavioral tendencies (including active alcohol or drug abuse) discovered during the screening process that in the opinion of the investigator would make compliance with the protocol difficult.
* History of anaphylactic or severe response to mosquito bites, retinal or visual field changes, or known allergy to the antimalarial chloroquine phosphate, which will be used to treat subjects developing malaria after CHMI.
* Participation in any study involving any investigational vaccine or drug within 30 days prior to the screening visit, or plan to participate in another investigational vaccine/drug research during or within 1 month following participation in this study.
* Use or planned use of any drug with antimalarial activity that would coincide with immunization or challenge.
* History of psoriasis or porphyria, which may be exacerbated after treatment with chloroquine.
* Anticipated use of medications known to cause drug reactions with chloroquine or atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and kaolin during the day 7 to 28 post-challenge period.
* Any other significant findings which, in the investigator's judgment, may substantially increase the risk associated with the subject's participation in the study or compromise the scientific objectives.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes